Company data sheet · Nasus Pharma
Nasus Pharma: three lost years, and the economy wasn't the reason.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Israel
- Ticker
- NSRX (NYSE)
- Sources
- SEC filings (2024–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Israel
- Data as of
- November 1, 2026
- From profit to three straight losses. Nasus Pharma lost money every year from 2023 to 2025: $0 billion in all.
- It wasn't the cycle. The losses began in 2023, a year Israel economy grew 2.1% and factories added jobs. When a company falls while its economy grows, look inside the company first.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2025 | $1.2 billion | −$0 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Israel, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.